Impact of the Beta-Glucan Test on Management of Intensive Care Unit Patients at Risk for Invasive Candidiasis - Université de Lille
Article Dans Une Revue Journal of Clinical Microbiology Année : 2020

Impact of the Beta-Glucan Test on Management of Intensive Care Unit Patients at Risk for Invasive Candidiasis

Résumé

The 1,3-beta- d -glucan (BDG) test is used for the diagnosis of invasive candidiasis (IC) in intensive care units (ICUs). However, its utility for patient management is unclear. This study assessed the impact of BDG test results on therapeutic decisions. This was a single-center observational study conducted in an ICU over two 6-month periods. All BDG test requests for the diagnosis of IC were analyzed. Before the second period, the ICU physicians received a pocket card instruction (algorithm) for targeted BDG testing in high-risk patients.

Dates et versions

hal-03288714 , version 1 (16-07-2021)

Identifiants

Citer

Antonios Kritikos, Julien Poissy, Antony Croxatto, Pierre-Yves Bochud, Jean-Luc Pagani, et al.. Impact of the Beta-Glucan Test on Management of Intensive Care Unit Patients at Risk for Invasive Candidiasis. Journal of Clinical Microbiology, 2020, Journal of clinical microbiology, 58 (6), ⟨10.1128/jcm.01996-19⟩. ⟨hal-03288714⟩

Collections

UNIV-LILLE
16 Consultations
0 Téléchargements

Altmetric

Partager

More